Research centre

Last updated on: 08/11/2019

1. Contact details{View data sources/studies associated with this centre}

Name of organisation

1) Department/Research groupClinical Pharmacology Department

2) Organisation/affiliationHospital La Paz, School of Medicine, UAM

Short Name in the inventoryClinical Pharmacology Department, HULP, UAM

Website/Homepage

Administrative Contact

Title Dr

Last name Ramirez

First name Elena

Address line 1Servicio de Farmacología Clínica

Address line 2Hospital Universitario la Paz

Address line 3Paseo de la Castellana, 261

CityMADRID

Postcode28046

CountrySpain

Phone number (incl. country code)34-91-7277559

Alternative phone number34-619505586

Fax number (incl. country code)34-91-7277559

Email address elena.ramirezg@uam.es

Scientific Contact

Title Dr

Last name Ramirez

First name Elena

Address line 1Servicio de Farmacología Clínica

Address line 2Hospital Universitario la Paz

Address line 3Paseo de la Castellana 261

CityMADRID

Postcode28046

CountrySpain

Phone number (incl. country code)34-91-7277559

Alternative phone number34-619505586

Fax number (incl. country code)34-91-7277559

Email address elena.ramirezg@uam.es

Alternative Scientific Contact

Title Professor

Last name Frias

First name Jesus

Address line 1Servicio de Farmacología Clínica

Address line 2Hospital Universitario la Paz

Address line 3Paseo de la Castellana 261

CityMADRID

Postcode28046

CountrySpain

Phone number (incl. country code)34-91-4975334

Alternative phone number34-91-4975364

Fax number (incl. country code)34-91-4975374

Email address jesus.frias@uam.es

2. Description

The Research experience and capabilities of our group are focus on the evaluation of efficacy, effectiveness and safety of drugs through: 1. Pharmacovigilance Program from Laboratory Signals at Hospital. It is prospective and based on the systematic detection of predefined abnormal laboratory signals that indicate serious reactions frequently related to the use of drugs. 2. Drug Utilization studies (DUS). The ultimate aim of a DUS is to achieve optimal therapeutic practice by describing the use of drugs, the qualitative assessment of the data to identify problems that enable the intervention on the identified problems. 3. Research and development of techniques and methods for personalization of drug treatments through the use of Therapeutic Drug Monitoring and Pharmacogenetics as a tool for the individualization of drug therapies. 4. Clinical trials to evaluate the Pharmacokinetics and pharmacodinamics of drugs.

3. Category

University based

Hospital based

4. Available resources

In houseVia Contacts/Network

9. Experience in secondary research and meta-analysis

10. Work with existing data resources in the past 3 years

None

11. Registries established by centre

Drug RegistryElectronic Prescriptions and administration (HCIS, HP)

Other Laboratory Signals Registry: Agranulocytosis, aplastic anaemia, thrombocytopenia, eosinophilia, hepatotoxicity, ARI, hyponatremia, rhabdomyolysis, K

12. Experience in collaboration in a study team

Principal Investigator

Collaborating Investigator

13. Current involvement in research networks

Networks registered with ENCePP

RegiSCAR

Other networks:

Network nameNationalInternationalLink to webpage

Consorcio PIELenRed Yes No http://pielenred.000webhostapp.com/PIELenRed/

Grupo Español para el Estudio de Hepatopatías Asociadas a Medicamentos Yes No http://www.spanishdili.uma.es/

La Paz Central Research and Clinical Trials Unit (Unidad Central de Investigación Clínica y Ensayos Clinicos de La Paz, HULP-UICEC) Yes No http://www.idipaz.es/PaginaDinamica.aspx?IdPag=187&Lang=EN

RegiSCAR No Yes http://www.regiscar.org/team.html

14. Interest in research opportunities which are funded

By pharmaceutical companies

By charities

By government

By research councils

15. Interest in contract research only if free to publish results

16. Selected publications of the last 5 calendar years

ReferenceLink to web-publication

Ramírez E, Rodríguez A, Queiruga J, García I, Díaz L, Martínez L, Muñoz R, Muñoz M, Tong HY, Martínez JC, Borobia AM, Carcas AJ, Frías J. Severe Hyponatremia Is Often Drug Induced: 10-Year Results of a Prospective Pharmacovigilance Program. Clin Pharmacol Ther. 2019 Jun 27. doi: 10.1002/cpt.1562.

Ramírez E, Bellón T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castañer JL, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Cachafeiro L, González-Herrada C, González O, Aramburu JA, Laosa O, Hernández R, Carcas AJ, Frías J. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res. 2017 Jan;115:168-178. doi: 10.1016/j.phrs.2016.11.027.

Dapía I, García I, Martinez JC, Arias P, Guerra P, Díaz L, García A, Ochoa D, Tenorio J, Ramírez E, Román M, Gordo G, Saiz-Rodríguez M, Frías J, Abad-Santos F, Lapunzina P, Carcas AJ, Borobia AM. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. Int J Antimicrob Agents. 2019 Oct;54(4):463-470. doi: 10.1016/j.ijantimicag.2019.06.026.

Ramírez E, Martín A, Villán Y, Lorente M, Ojeda J, Moro M, Vara C, Avenza M, Domingo MJ, Alonso P, Asensio MJ, Blázquez JA, Hernández R, Frías J, Frank A; SINOIRES Working Group. Effectiveness and limitations of an incident-reporting system analyzed by local clinical safety leaders in a tertiary hospital: Prospective evaluation through real-time observations of patien safety incidents. Medicine (Baltimore). 2018 Sep;97(38):e12509. doi: 10.1097/MD.0000000000012509.

Ramírez E, Romero-Garrido JA, López-Granados E, Borobia AM, Medrano N, Rueda C, Tong HY, Herrero A, Frías J. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res. 2014; 133(6):1045-51.

Top